Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics

Neuromelanin accumulates in dopaminergic neurons during normal aging, and in Parkinson's disease, neurons with this pigment are those that selectively degenerate. Intraneuronal neuromelanin could play a protective role during its synthesis by preventing the toxic accumulation of cytosolic catechol derivatives and, in addition, by its ability to scavenge reactive metals, pesticides and other toxins to form stable adducts. However, dying neurons in Parkinson's disease that release neuromelanin might induce a vicious cycle of chronic neuroinflammation and neuronal loss.

[1]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[2]  P. Riederer,et al.  Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins , 2000, Journal of neurochemistry.

[3]  T. Sokoloski,et al.  Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. , 1978, Federation proceedings.

[4]  L. Pannell,et al.  Enzyme Activity of Macrophage Migration Inhibitory Factor toward Oxidized Catecholamines* , 1999, The Journal of Biological Chemistry.

[5]  J. Foley,et al.  ON THE NATURE OF PIGMENT GRANULES IN THE CELLS OF THE LOCUS COERULEUS AND SUBSTANTIA NIGRA , 1958, Journal of neuropathology and experimental neurology.

[6]  T. Hastings.  Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.

[7]  G. Fenichel,et al.  Studies on neuromelanin: II. Melanin in the brainstems of infants and children , 1968, Neurology.

[8]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[9]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[10]  B. Bergamasco,et al.  Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. , 2000, Biochimica et biophysica acta.

[11]  D. Radice,et al.  Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.

[12]  M Gallorini,et al.  Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes , 2001, Journal of neurochemistry.

[13]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[14]  N. Lindquist,et al.  Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: Accumulation in neuromelanin , 1988, Neuroscience Letters.

[15]  F Beermann,et al.  New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. , 1998, Brain research. Molecular brain research.

[16]  Marsden Cd.  Pigmentation in the nucleus substantiae nigrae of mammals. , 1961 .

[17]  R. Fariello,et al.  Neuromelanic pigment in substantia nigra neurons of rats and dogs , 1986, Neuroscience Letters.

[18]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[19]  D. Graham.  On the origin and significance of neuromelanin. , 1979, Archives of pathology & laboratory medicine.

[20]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[21]  S. Ito,et al.  Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? , 1998, Neuroscience Letters.

[22]  T. Sarna,et al.  The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.

[23]  V. Tennyson,et al.  Phase and Electron Microscopic Observations of Lewy Bodies and Melanin Granules in the Substantia Nigra and Locus Caeruleus in Parkinson's Disease , 1965 .

[24]  E. Rosengren,et al.  Neuromelanin of the Human Substantia Nigra: A Mixed‐Type Melanin , 1994, Journal of neurochemistry.

[25]  H. M. Swartz,et al.  Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.

[26]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Alberto Gatti,et al.  The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.

[28]  Y. Agid,et al.  Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? , 1992, Journal of neurochemistry.

[29]  A H Stokes,et al.  Tyrosinase mRNA is expressed in human substantia nigra. , 1997, Brain research. Molecular brain research.

[30]  T. Shima,et al.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.

[31]  G. Deuschl,et al.  Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  M. G. Bridelli,et al.  The structure of neuromelanin and its iron binding site studied by infrared spectroscopy , 1999, FEBS letters.

[33]  G. C. Cotzias,et al.  MELANOGENESIS AND EXTRAPYRAMIDAL DISEASES. , 1964, Federation proceedings.

[34]  S. Ito,et al.  Interaction of Human Substantia Nigra Neuromelanin with Lipids and Peptides , 2000, Journal of neurochemistry.

[35]  K. Wakamatsu,et al.  The structure of neuromelanin as studied by chemical degradative methods , 2003, Journal of neurochemistry.

[36]  A. Carlsson,et al.  Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species , 1986, Neuropharmacology.